1 / 9

ACE2

anti-sense. sense. a. b. c. 1.0. ACE. O kg/ml). 0.8. 0.6. ACE2. 0.4. Elastance (cmH 2. 0.2. WT. ace2 KO. 0.0. WT. ace2 KO. Supplementary Figure 1. c. a. *. Wet / dry ratio. WT, LPS. WT, saline. ace2 KO, saline. ace2 KO, LPS. 8. 7. 6. 5. 4. b.

burt
Télécharger la présentation

ACE2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. anti-sense sense a b c 1.0 ACE O kg/ml) 0.8 0.6 ACE2 0.4 Elastance (cmH2 0.2 WT ace2 KO 0.0 WT ace2 KO Supplementary Figure 1

  2. c a * Wet / dry ratio WT, LPS WT, saline ace2 KO, saline ace2 KO, LPS 8 7 6 5 4 b ace2 KO, LPS+Zymosan WT, LPS+Zymosan 150 WT ace2 KO, saline WT, saline 100 % Changes in elastance 50 ace2 KO 0 0 1 2 3 hrs LPS Zymosan Supplementary Figure 2

  3. rhuACE2 2.5 Mut-rhuACE2 Mut-rhuACE2 rhuACE2 2.0 → 175KD 1.5 rhuACE2s Arbitary unit/hr → 83KD → 1.0 62KD Bovine IgG → 48KD 0.5 → 33KD 0 → 1 10 100 (ng/ml) 25KD 9 8 * 7 Wet / dry ratio 6 5 4 rhuACE2 rhuACE2 Mut-rhuACE2 Mut-rhuACE2 acid saline Wild type a b c Supplementary Figure 3

  4. * 4 600 6 600 3 400 AngII (fmol/ml) 4 Ang II (fmol/mg protein) 2 400 Ang II (fmol/mg protein) AngII (fmol/ml) * 200 1 2 200 0 ** ** ** ** 0 0 0 WT, acid ace2 KO, acid WT, control ace2 KO, control WT, acid WT, acid WT, acid ace-/-, acid ace2 KO, acid ace-/-, acid ace2 KO, acid WT, acid, rhuACE2 ace-/-ace2 KO, acid ace-/- ace2 KO, acid a b c d Supplementary Figure 4

  5. 7 * * 6 Wet /dry ratio 5 4 WT, acid WT, saline ace+/-, acid ace-/-, acid ace-/-, saline Supplementary Figure 5

  6. WT, LPS+Zymosan ace+/+ ace2 KO , LPS+Zymosan 150 ace-/- ace2 KO , LPS+Zymosan WT, saline ace-/- ace2 KO, saline 100 % Changes in elastance 50 0 0 1 2 3 hrs LPS Zymosan Supplementary Figure 6

  7. a b * 8 10 7 * Wet / dry ratio 8 Wet / dry ratio 6 * 6 5 4 4 WT, acid WT, saline agtr2-/y, acid agtr1a-/-, acid ace2 KO, saline, vehicle ace2 KO, acid, vehicle ace2 KO, saline, AT1R inhibitor ace2 KO, acid, AT1R inhibitor Supplementary Figure 7

  8. a b WT 12 WT 10 ace2 KO ace2 KO 10 8 8 Pperf (cmH2O) Pperf (cmH2O) 6 6 4 4 D D 2 2 0 0 Acid: + LPS: + + + AngI inj. AngII inj. AngI inj. AngII inj. Supplementary Figure 8

  9. 0.5 0.4 0.3 Fractional shortening acid 0.2 WT, acid 0.1 ace2 KO, acid 0 hrs 0 1 2 3 80 60 (mmHg) 40 Mean arterial pressure acid WT, acid 20 agtr1a-/-, acid 0 0 1 2 3 hrs a b 80 60 (mmHg) Mean arterial pressure 40 acid 20 WT, acid ace2 KO, acid 0 hrs 0 1 2 3 c Supplementary Figure 9

More Related